Project Grant R41CA301978
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Immunogenik, Inc. (XGX9CKVE5N68)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...
This federal Project Grant award of $398,997.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Immunogenik, Inc. in Gainesville, Florida aims to advance cancer therapy by developing an antibody blockade targeting the novel immune checkpoint, LAIR1/CD305. The key objectives are to: 1) validate a lead human anti-LAIR1 antibody candidate in vitro, 2) conduct efficacy studies in tumor-bearing mice to identify the optimal dose, and 3) perform pilot safety and...
The National Cancer Institute (NCI) awarded a $222,998 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) for the period of March 10, 2025 to February 28, 2027. The grant supports research to engineer endogenous immune cells, including T cells, NK cells, and macrophages, to express chimeric antigen receptors (CARs) using a novel virus-like particle (VLP) vector. The goal is to enable these engineered immune cells to mediate...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,272 project grant to The Johns Hopkins University on Feb 24, 2025 to develop and optimize engineered, self-propelled tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) to enhance their migration speed and tumor infiltration capabilities. The goal is to improve the efficacy of CAR T cell therapy for treating pancreatic cancer, which has a 5-year survival rate of just ~12%....
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1,220,394 project grant to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on September 15, 2024, will fund research to comprehensively characterize the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The research aims to investigate the molecular...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is providing $748,337 to Pyrojas Inc. to develop an innovative "Pyrotimer" CAR-T cell therapy. The goal is to create a more potent and persistent CAR-T cell treatment that can overcome the immunosuppressive tumor microenvironment, particularly by inhibiting transforming growth factor-beta (TGF-β). The research plan involves extensive in vitro and in vivo...